Home › Research › MOTS-c
RESEARCH USE ONLY — This article describes a compound studied in laboratory and pre-clinical research. It is not intended for human or animal administration.

MOTS-c

Mitochondrial / Longevity Half-life: ~3 hours Status: Research Compound

MOTS-c

Overview

MOTS-c (Mitochondrial Open Reading Frame of the 12S rRNA Type-c) is an endogenous mitochondrial-derived peptide (MDP) encoded within the mitochondrial genome. Discovered in 2015 by Dr. Changhan David Lee's laboratory at USC, it is notable for being one of the first identified signaling peptides encoded by mitochondrial DNA rather than nuclear DNA. MOTS-c has garnered significant research interest as a potential exercise mimetic and metabolic regulator.

BLUF — At a Glance

An endogenous mitochondrial-derived peptide encoded within the mitochondrial genome, studied in metabolic-regulation research.

Primary research focus

  • Glucose homeostasis and metabolic regulation
  • Fatty-acid oxidation
  • Age-related metabolic-function research

Notes: Status: research compound — not FDA-approved. Half-life ~3 hr. Human clinical safety data sparse; evidence largely animal-model. For research purposes only.

Mechanism of Action

MOTS-c acts as a retrograde signaling molecule from mitochondria to the nucleus, regulating metabolic homeostasis through the AMPK (AMP-activated protein kinase) pathway. It activates AMPK signaling, which promotes glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. Published research shows MOTS-c inhibits the folate cycle and de novo purine biosynthesis, leading to AICAR accumulation, which in turn activates AMPK. Under metabolic stress, MOTS-c translocates to the nucleus where it regulates gene expression related to antioxidant defense and glucose metabolism, effectively acting as a mitochondrial-to-nuclear communication signal.

Research-Indicated Benefits

  • Published research suggests MOTS-c activates AMPK signaling pathways that mimic the metabolic effects of exercise
  • Published research suggests improvements in insulin sensitivity and glucose homeostasis in diet-induced obesity animal models
  • Published research suggests enhanced fatty acid oxidation and prevention of age-dependent and diet-induced obesity
  • Published research suggests protection against metabolic stress and improved cellular energy regulation
  • Published research suggests that endogenous MOTS-c levels decline with age, correlating with age-related metabolic dysfunction

Typical Research Protocols

Commonly reported in research literature: 5-10 mg administered subcutaneously, with dosing frequency varying across published studies from daily to several times per week. Most published data comes from animal model studies (primarily murine), with limited human clinical data available. Research protocols in animal models have typically spanned 2-8 weeks.

Safety Profile

Published research on MOTS-c safety is limited primarily to animal model studies. In murine models, no significant adverse effects have been reported at the studied doses. As an endogenous peptide naturally present in human plasma, the theoretical safety profile may be favorable, but human clinical safety data remains sparse. Circulating MOTS-c levels have been measured in human plasma and shown to decline with age and in metabolic disease states.

Key Studies

  • Lee C, et al. "The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance." Cell Metabolism, 2015.
  • Kim KH, et al. "MOTS-c mediates nuclear gene regulation through an AMPK-dependent mechanism." Cell Metabolism, 2018.
  • Reynolds JC, et al. "MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis." Nature Communications, 2021.
  • Multiple studies in metabolic and mitochondrial biology journals have investigated MOTS-c's role in cellular energy regulation and aging.

Interactions and Stacking

Epithalon and GHK-Cu are discussed in complementary longevity and cellular health research contexts through distinct mechanisms (telomerase activation and copper-dependent tissue remodeling, respectively). AOD-9604 and Semaglutide target metabolic and weight management pathways through different receptor systems, offering mechanistically distinct approaches to the metabolic research questions that MOTS-c addresses through mitochondrial signaling.

For research and educational purposes only. Not medical advice.

Frequently Asked Questions

Is MOTS-c FDA-approved?

No. MOTS-c is not approved by the U.S. Food and Drug Administration for any clinical application. It remains classified as a research compound supplied for laboratory work only.

What does the research literature show about MOTS-c?

The published research record for MOTS-c is summarized in the body of this article and the citations section. Pre-clinical and animal-model studies make up the bulk of the literature; human trial data is limited and is noted explicitly where it exists.

What are the documented synergistic compounds for MOTS-c research?

See the Related Research sidebar for compounds that appear alongside MOTS-c in the published literature. Detailed synergy notes will populate during the next vault expansion pass.

Where can I source MOTS-c for research purposes?

See the Where to Source section above for vendors that supply research-grade MOTS-c. Listed vendors are affiliate partners of Peptide Manager Pro; we earn a small commission on referred orders at no additional cost to the buyer.

Is MOTS-c safe for human or animal use?

MOTS-c is sold for in vitro and laboratory research only. It is not intended for human or veterinary administration, and no safety determination for such use has been established by the U.S. Food and Drug Administration or any equivalent regulatory body.